New Criteria for Response to Treatment in Immunoglobulin Light Chain Amyloidosis Based on Free Light Chain Measurement and Cardiac Biomarkers: Impact on Survival Outcomes

• Published in: Journal of clinical oncology Vol. 30; no. 36; pp. 4541 - 4549
• Main Authors: Palladini, Giovanni, Dispenzieri, Angela, Gertz, Morie A., Kumar, Shaji, Wechalekar, Ashutosh, Hawkins, Philip N., Schönland, Stefan, Hegenbart, Ute, Comenzo, Raymond, Kastritis, Efstathios, Dimopoulos, Meletios A., Jaccard, Arnaud, Klersy, Catherine, Merlini, Giampaolo
• Format: Journal Article
• Language: English
• Published: Alexandria, VA American Society of Clinical Oncology 20.12.2012
• Subjects: Aged; Amyloidosis; Amyloidosis - blood; Amyloidosis - drug therapy; Amyloidosis - surgery; Amyloidosis - therapy; Biological and medical sciences; Biological Markers; Biomarkers - blood; Cohort Studies; Dexamethasone; Dexamethasone - therapeutic use; Female; Humans; Immunoglobulin Light Chains; Immunoglobulin Light Chains - blood; Immunology; Life Sciences; Male; Medical sciences; Melphalan; Melphalan - therapeutic use; Middle Aged; Retrospective Studies; Stem Cell Transplantation; Survival Analysis; Tumors; Heart; AL amyloidosis; Immunoglobulins; Cancerology; Prognosis; Treatment efficiency; Biological marker; Circulatory system; Light peptide chain; Survival

To identify the criteria for hematologic and cardiac response to treatment in immunoglobulin light chain (AL) amyloidosis based on survival analysis of a large patient population. We gathered for analysis 816 patients with AL amyloidosis from seven referral centers in the European Union and the Unit...